Tags

Type your tag names separated by a space and hit enter

Pharmacology of the phosphate binder, lanthanum carbonate.
Ren Fail. 2011; 33(2):217-24.RF

Abstract

Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum hydroxide markedly increased excretion of [(32)P]-phosphate in feces and reduced excretion in urine in rats with normal renal function (p < 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum carbonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary pharmacological actions were observed in vivo in a systematic evaluation at high doses.

Authors+Show Affiliations

Shire Pharmaceuticals, Hampshire International Business Park, Chineham, Basingstoke, UK. sdamment@shire.com

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21332344

Citation

Damment, Stephen J P.. "Pharmacology of the Phosphate Binder, Lanthanum Carbonate." Renal Failure, vol. 33, no. 2, 2011, pp. 217-24.
Damment SJ. Pharmacology of the phosphate binder, lanthanum carbonate. Ren Fail. 2011;33(2):217-24.
Damment, S. J. (2011). Pharmacology of the phosphate binder, lanthanum carbonate. Renal Failure, 33(2), 217-24. https://doi.org/10.3109/0886022X.2011.552821
Damment SJ. Pharmacology of the Phosphate Binder, Lanthanum Carbonate. Ren Fail. 2011;33(2):217-24. PubMed PMID: 21332344.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacology of the phosphate binder, lanthanum carbonate. A1 - Damment,Stephen J P, PY - 2011/2/22/entrez PY - 2011/2/22/pubmed PY - 2011/6/17/medline SP - 217 EP - 24 JF - Renal failure JO - Ren Fail VL - 33 IS - 2 N2 - Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum hydroxide markedly increased excretion of [(32)P]-phosphate in feces and reduced excretion in urine in rats with normal renal function (p < 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum carbonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary pharmacological actions were observed in vivo in a systematic evaluation at high doses. SN - 1525-6049 UR - https://www.unboundmedicine.com/medline/citation/21332344/Pharmacology_of_the_phosphate_binder_lanthanum_carbonate_ L2 - https://www.tandfonline.com/doi/full/10.3109/0886022X.2011.552821 DB - PRIME DP - Unbound Medicine ER -